Agaricus Blazei Mushroom for Liver and Antioxidant Support

Liver and Antioxidant Support — scientific infographic poster

This page carries an unusual duty: it presents both the promising and the cautionary sides of Agaricus blazei and the liver, because the honest evidence points in two directions at once. On one hand, the mushroom's polysaccharides show antioxidant activity in the laboratory, and in animal models they protect the liver against chemical injury. On the other hand, there are real published case reports of severe liver injury in people — particularly cancer patients — who took Agaricus supplements. Both things are true. The antioxidant biology is genuine but mostly preclinical; the human liver-injury reports are rare but serious. Understanding this paradox is essential to using the mushroom sensibly, and it is the reason “natural” can never be assumed to mean “safe for the liver.”


Table of Contents

  1. What “Antioxidant” Actually Means Here
  2. Polysaccharide Antioxidant Studies
  3. Hepatoprotection in Chemical Liver-Injury Models
  4. Protecting Liver Cells from Genotoxins
  5. Liver Carcinogenesis Models: A Mixed Picture
  6. A Small Human Signal: Chronic Hepatitis B
  7. Beyond the Liver: Systemic Oxidative Parameters
  8. The Important Paradox: Case Reports of Liver INJURY
  9. Who the Research Raises Concerns For
  10. Practical Notes
  11. Key Research Papers
  12. External Resources
  13. Connections
  14. Featured Videos

What “Antioxidant” Actually Means Here

“Antioxidant” is one of the most overused words in supplement marketing, so it is worth being precise. In the Agaricus blazei literature it refers to two related things: (1) the direct chemical ability of the mushroom's compounds to neutralize reactive free radicals in a test tube (measured by assays such as the 1,1'-diphenyl-2-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical tests, and hydroxyl-radical scavenging), and (2) the biological ability, in cells and animals, to reduce markers of oxidative damage such as lipid peroxidation (measured as malondialdehyde) and to support the body's own antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase.

The liver is the organ where this matters most, because the liver is the body's chemical-processing plant. It detoxifies drugs, alcohol, and environmental toxins, and that work generates a heavy load of reactive oxygen species. Many forms of liver damage — from alcohol, from certain drugs, from fatty-liver disease — involve oxidative stress. An agent that genuinely reduces hepatic oxidative stress is therefore biologically plausible as a liver protectant, which is exactly the hypothesis the animal studies test.

A note on the name: the cultivated mushroom sold in Brazil and Japan as “Agaricus blazei” has also been sold as A. brasiliensis. A 2005 study based on DNA sequence analysis, mating studies and the genetics of hybrid offspring found a strong case that it is the same species as Agaricus subrufescens Peck, a mushroom first cultivated in the late 1800s in eastern North America. Some newer studies, including one on this page, use the name A. subrufescens.

Back to Table of Contents

Polysaccharide Antioxidant Studies

Multiple studies confirm that polysaccharides extracted from Agaricus blazei have measurable antioxidant activity, and — importantly for anyone buying a product — that the strength of that activity depends heavily on how the mushroom is processed. Research has shown that the drying method changes the antioxidant properties of the extracted polysaccharides, and that different extraction methods yield polysaccharides with different antioxidant capacities. A 2008 study of a different, newly identified fungus (Basidiomycetes-X) tested a hot-water extract of Agaricus blazei as a comparator: the Agaricus extract showed antioxidant activity in test-tube assays and protected mouse livers against oxidative damage caused by bacterial lipopolysaccharide, but in both settings it was weaker than the extract of the new fungus.

The practical lesson from this processing-sensitivity is the same one that runs through all Agaricus blazei research: the “same” mushroom can be weak or strong depending on cultivation, drying, and extraction, which makes standardization and third-party testing genuinely important and makes cross-study comparison difficult.

Back to Table of Contents

Hepatoprotection in Chemical Liver-Injury Models

The most direct animal evidence for liver protection comes from carbon tetrachloride (CCl4) models. CCl4 is a classic laboratory hepatotoxin: the liver metabolizes it into a reactive radical that triggers lipid peroxidation and cell death, producing a reliable, reproducible pattern of liver injury that researchers use to test protective agents. In these models, Agaricus blazei Murill extract reduced CCl4-induced liver injury in rats, and a separate study reported that the mushroom acted as an efficient hepatoprotective and antioxidant agent against CCl4-induced injury, with lower liver-enzyme elevations and reduced markers of oxidative damage in the treated animals.

These are among the more convincing preclinical results for the mushroom, because they combine a clear injury model with a measurable protective effect. The mechanism is less clear than the result. In the first of these studies (2011), the high dose (2,000 mg of extract per kilogram) reduced liver necrosis and fibrosis, and the treated rats had lower blood levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST); but the liver's antioxidant enzymes (glutathione peroxidase, superoxide dismutase and catalase) showed no apparent differences from the untreated CCl4 rats, and the authors concluded that removal of free radicals does not explain the protection they observed. The honest boundary is that CCl4 poisoning in a rat is not human liver disease, and protecting a rat from an industrial solvent does not establish that the mushroom protects human livers from alcohol, medication, or fatty-liver disease.

Animal work on alcohol-related liver injury continues. In a 2026 mouse study, a crude polysaccharide from Agaricus subrufescens (the same species, see the name note above) lowered serum alanine aminotransferase by 36.22% and aspartate aminotransferase by 31.65% and liver malondialdehyde by 33.19% after alcohol exposure, and raised the antioxidant enzymes superoxide dismutase, glutathione peroxidase and catalase by 12.04%, 9.76% and 18.45%. This is an animal result, not a human one.

Back to Table of Contents

Protecting Liver Cells from Genotoxins

A related line of work uses HepG2 cells, a human liver-derived cell line, to test whether Agaricus blazei compounds can protect liver-cell DNA from damage. A beta-glucan extracted from Agaricus blazei prevented the genotoxic (DNA-damaging) effects of benzo[a]pyrene — a carcinogen from smoke and charred food — in these human liver cells. This connects the mushroom's antioxidant activity to a potential protective role against DNA-level injury, and it overlaps with the chemoprevention discussion on the Cancer Research page.

As with all cell-line work, this demonstrates a mechanism under controlled conditions; it does not establish that consuming the mushroom protects a living person's liver from carcinogens.

Back to Table of Contents

Liver Carcinogenesis Models: A Mixed Picture

Honesty requires presenting the inconsistent results in the liver-cancer prevention models. Using diethylnitrosamine (DEN), a chemical that initiates liver cancer in rats, different studies reached different conclusions. Some reported that dietary Agaricus blazei reduced the development of preneoplastic (precancerous) liver foci and influenced DEN-induced liver toxicity favorably. Yet another carefully conducted study found that Agaricus blazei (Himematsutake) did not alter the development of DEN-initiated hepatic preneoplastic foci at all.

This split is informative rather than embarrassing. It tells us that any chemopreventive effect on the liver is, at best, modest and dependent on the specific extract, dose, and timing — not a robust, reliable phenomenon. Presenting only the positive studies would misrepresent the evidence; the balanced reading is “possible weak effect, not consistently reproducible.”

Back to Table of Contents

A Small Human Signal: Chronic Hepatitis B

There is one small human study worth mentioning with appropriate caution. In patients with chronic hepatitis B, an Agaricus blazei Murill extract was reported to help normalize liver function (improve elevated liver-enzyme levels). It was a 1-year open-label pilot study with no control group: four patients with hepatitis B took 1,500 mg of the extract daily for 12 months, and their mean alanine aminotransferase fell from 151.0 to 46.1 IU/L and their mean aspartate aminotransferase from 246.0 to 61.3 IU/L. This is an intriguing signal because it is one of the few pieces of human liver data, and hepatitis B is a major cause of liver disease worldwide.

The caveats are substantial: it is a small study, liver enzymes are a surrogate marker rather than a hard outcome like reduced cirrhosis or liver cancer, and it has not been replicated in large independent trials; the authors themselves wrote that controlled studies with larger samples are needed. It is a hypothesis-generating observation, not evidence that Agaricus blazei treats hepatitis B — a condition for which effective antiviral medications exist; the study made no comparison with them. See our Hepatitis B page for the standard picture.

Hepatitis C has been looked at even more briefly. In a 2006 study of four patients with chronic hepatitis C, the viral load fell slightly, but not significantly, after 1 week of an Agaricus blazei extract, and the immune-signal (cytokine) genes the extract had switched on most strongly in test-tube work were not switched on in the patients' blood cells. The authors suggested that the extract's beta-glucans did not readily enter the blood.

Back to Table of Contents

Beyond the Liver: Systemic Oxidative Parameters

The mushroom's antioxidant reach has been probed in other tissues too. In one study, treating old rats with an aqueous Agaricus blazei extract improved oxidative and functional parameters in brain tissue and brain mitochondria, suggesting the antioxidant effect is systemic rather than confined to the liver. This fits the general theme of the mushroom acting as a mild, broad antioxidant support rather than a targeted drug.

These findings are preliminary and animal-based, and aging-brain models are notoriously hard to translate. They are best understood as evidence that the antioxidant activity is real and body-wide in animals, not as a claim about protecting human brains.

Back to Table of Contents

The Important Paradox: Case Reports of Liver INJURY

Here is the crucial counterweight to everything above. Despite the mushroom's hepatoprotective reputation in animal studies, there are published human case reports of serious liver injury associated with Agaricus supplements. A notable report described severe hepatic dysfunction in cancer patients that may have been induced by an Agaricus health-food product. This is not a contradiction that can be waved away; it is a real and important safety signal.

That 2006 report described three patients with advanced cancer who developed severe liver damage while taking an Agaricus blazei extract; two of them died of fulminant hepatitis. In one patient, liver function recovered gradually after she stopped the extract and worsened again when she restarted it; the other two had started the extract several days before they were admitted with severe liver damage. The authors noted that other causes could not be completely ruled out. A 2013 report described two more cases in people with stable cancers: a 60-year-old woman taking Agaricus blazei extract together with a Ganoderma lucidum extract, and a 75-year-old man taking it together with fucoidan. Both cases were judged compatible with drug-induced liver injury on an international scale (the Roussel Uclaf Causality Assessment Method), in both the liver tissue looked very similar to autoimmune hepatitis, and the authors suggested that the mushroom's immune-stimulating action caused the injury. A 2025 case report described a 43-year-old woman with metastatic colorectal cancer and liver metastases whose blood tests before chemotherapy showed grade 3 hepatic cytolysis (liver-cell injury) and cholestasis, after normal baseline results. She had been taking three mushroom-powder capsules a day containing Agaricus blazei and Hericium erinaceus. Her chemotherapy was cancelled, the supplement was stopped, and her liver function improved; the authors judged the injury likely linked to the Agaricus despite her liver metastases.

How can an antioxidant mushroom that protects rat livers also be linked to human liver injury? Several explanations are plausible and not mutually exclusive:

The take-home message is not “the mushroom is dangerous” nor “the mushroom is protective” — it is that both protective and harmful effects have been observed, that individual responses vary, and that the published human liver-injury cases involved supplement products (extracts and powder capsules).

Back to Table of Contents

Who the Research Raises Concerns For

Liver injury shows up on the liver-function blood tests (alanine aminotransferase and aspartate aminotransferase). In the 2006 report, two patients were admitted with severe liver damage several days after starting the extract, and in a third the damage returned when she restarted it after recovering.

Back to Table of Contents

Practical Notes

For general antioxidant use in people without liver disease, food-grade quantities of the mushroom are a different exposure from high-dose concentrated extracts, and the quality of products varies; independent (third-party) testing is one way quality is checked. The signs of liver trouble are unusual fatigue, nausea, right-upper-abdomen discomfort, dark urine, pale stools, and yellowing of the skin or eyes (jaundice); these are signs of liver injury that hospitals treat as urgent. In the 2006 report one patient's liver function recovered gradually after she stopped the extract, and in the 2025 report liver function improved after the supplement was stopped. Because Agaricus mushrooms concentrate cadmium and other metals from soil, heavy-metal testing is a meaningful quality marker for this species in particular.

The liver-injury reports on this page involved supplement products, not the mushroom eaten as food. Whole antioxidant-rich foods — colorful vegetables and fruit, other culinary mushrooms, and a varied diet — are another source of dietary antioxidants.

Back to Table of Contents

Key Research Papers

  1. Al-Dbass AM, et al. (2012). Agaricus blazei Murill as an efficient hepatoprotective and antioxidant agent against CCl4-induced liver injury in rats. Saudi Journal of Biological Sciences — PubMed PMID: 23961190
  2. Wu MF, et al. (2011). Agaricus blazei Murill extract abrogates CCl4-induced liver injury in rats. In Vivo — PubMed PMID: 21282732
  3. Angeli JP, et al. (2009). Beta-glucan extracted from the medicinal mushroom Agaricus blazei prevents the genotoxic effects of benzo[a]pyrene in the human hepatoma cell line HepG2. Archives of Toxicology — PubMed PMID: 18528685
  4. Watanabe T, et al. (2008). In vitro and in vivo anti-oxidant activity of hot water extract of basidiomycetes-X, newly identified edible fungus. Biological and Pharmaceutical Bulletin — PubMed PMID: 18175952
  5. Wu S, et al. (2014). Drying effects on the antioxidant properties of polysaccharides obtained from Agaricus blazei Murrill. Carbohydrate Polymers — PubMed PMID: 24528748
  6. Jia S, et al. (2013). Effects of extraction methods on the antioxidant activities of polysaccharides from Agaricus blazei Murrill. International Journal of Biological Macromolecules — PubMed PMID: 23994789
  7. Pinheiro F, et al. (2003). Chemoprevention of preneoplastic liver foci development by dietary mushroom Agaricus blazei Murrill in the rat. Food and Chemical Toxicology — PubMed PMID: 12963007
  8. Barbisan LF, et al. (2002). Influence of aqueous extract of Agaricus blazei on rat liver toxicity induced by different doses of diethylnitrosamine. Journal of Ethnopharmacology — PubMed PMID: 12413704
  9. Barbisan LF, et al. (2003). Agaricus blazei (Himematsutake) does not alter the development of rat diethylnitrosamine-initiated hepatic preneoplastic foci. Cancer Science — PubMed PMID: 12708495
  10. Hsu CH, et al. (2008). The mushroom Agaricus blazei Murill extract normalizes liver function in patients with chronic hepatitis B. Journal of Alternative and Complementary Medicine — PubMed PMID: 18370584
  11. de Sá-Nakanishi AB, et al. (2014). Effects of treating old rats with an aqueous Agaricus blazei extract on oxidative and functional parameters of the brain tissue and brain mitochondria. Oxidative Medicine and Cellular Longevity — PubMed PMID: 24876914
  12. Mukai H, et al. (2006). An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Japanese Journal of Clinical Oncology — PubMed PMID: 17105737
  13. Hisamochi A, et al. (2013). Drug-induced liver injury associated with Agaricus blazei Murill which is very similar to autoimmune hepatitis. Clinical Journal of Gastroenterology — PubMed PMID: 26181451
  14. Strobbe G, et al. (2025). Grade 3 cytolysis in a patient with metastatic colorectal cancer consuming a mushroom powder-based alternative therapy. Journal of Oncology Pharmacy Practice — PubMed PMID: 39223928
  15. Grinde B, et al. (2006). Effects on gene expression and viral load of a medicinal extract from Agaricus blazei in patients with chronic hepatitis C infection. International Immunopharmacology — PubMed PMID: 16782544
  16. Kerrigan RW (2005). Agaricus subrufescens, a cultivated edible and medicinal mushroom, and its synonyms. Mycologia — PubMed PMID: 16389952
  17. Wang Z, et al. (2026). The Crude Polysaccharide Derived from Agaricus subrufescens Alleviates Alcoholic Liver Injury. Foods — PubMed PMID: 41976536

PubMed Topic Searches

  1. PubMed: Agaricus blazei hepatoprotective
  2. PubMed: Agaricus blazei antioxidant polysaccharide
  3. PubMed: Agaricus blazei liver injury
  4. PubMed: Agaricus blazei hepatitis B
  5. PubMed: Agaricus blazei oxidative stress
  6. PubMed: mushroom supplement hepatotoxicity

Back to Table of Contents

External Resources

Back to Table of Contents

Connections

Back to Table of Contents